MolGenBio: FK506 Derivative Hair Growth Drug

By Follicle Thought | October 4, 2022 |

A new Korean biotech company seeks to leverage the multi-faceted therapeutic benefit of FK506 to create a newer and safer hair growth drug. As we are gratified to see completely new approaches emerge in the hair growth space, we should also value the strategy of creating new and improved iterations of older hair growth drugs…

Read More

Epibiotech Prepares For Important Clinical Trial, Pig Study Results & More

By Follicle Thought | September 22, 2022 |

Epibiotech continues to announce important milestones and progress leading up to a Phase 1 clinical trial for its cell therapy in AGA. Innovative Drug Discovery For Hair-Loss Therapy Symposium Earlier this year in June, Epibiotech co-hosted a hair loss research conference in South Korea with Yonsei University’s Pharmaceutical Research Institute. The meeting, titled “Innovative Drug…

Read More

Kintor Pharmaceutical KX-826 Phase 2 Results With Poster

By Follicle Thought | August 29, 2022 |

The long awaited phase II results from Kintor’s KX-826 (pyrilutamide) study in males with androgenetic alopecia have surfaced online. KX-826 Phase 2 Results Presentation Several months ago in May, the 28th Annual Meeting of the Chinese Society of Dermatology was postponed from June to the beginning of September 2022. This was the acclaimed conference where…

Read More

“Bad Hair Day” Series Debuts On TLC

By Follicle Thought | August 23, 2022 |

A new reality tv series about people seeking solutions for hair loss, alopecia, and other dermatology-related conditions is coming soon to the TLC channel. Reality TV Hair Loss Show Much in the spirit of the “Dr. Pimple Popper” show, the TLC television network is rolling out a new medically-focused reality show featuring three female hair…

Read More

Cutia Therapeutics: CU-40101 New Drug For Hair Loss 2022

By Follicle Thought | August 16, 2022 |

A new drug aimed at the treatment of androgenetic alopecia is entering a phase 1 clinical trial imminently as of August 2022. CU-40101 Phase 1 Clinical Trial Cutia Therapeutics is the latest biotechnology company to emerge from behind the scenes and enter the global race for new androgenetic alopecia therapies. Its candidate molecule CU-40101 is…

Read More

4-Aminopyridine Wound Healing & Hair Growth

By Follicle Thought | July 29, 2022 |

An FDA approved drug is currently being researched for its repurposed potentials in wound regeneration and hair regrowth. 4-Aminopyridine is a prescription medicine used for the treatment of multiple sclerosis. It’s marketed under the brand name Ampyra and is classified as a potassium channel blocker. This compound, also known as 4-AP or dalfampridine, was the…

Read More

The Best Of Hair Transplants 2022

By Follicle Thought | July 12, 2022 |

This article contains a wealth of information on hair transplant surgery, photographic examples of hair transplant results, and practical guidance on how to make the right decisions when considering a hair transplant surgeon. Hair Transplant Surgery – 2022 Hair transplants have become an increasingly popular topic over the past several years as multiple celebrities, sports…

Read More

Exosomes Therapies For Hair Loss

By Follicle Thought | June 15, 2022 |

Several new companies are developing exosome therapies to treat hair loss. Unlike previous iterations of exosomes treatments, these therapies will undergo clinical trials within the FDA approval process. Exosomes And Hair Growth Around two years ago, exosomes became the latest hot topic in hair restoration and hair loss treatments. Various hair transplant surgeons and dermatologists…

Read More